Eurofins Central Laboratory has over 20 years of experience in Kit Packing and Distribution Services. We provide sample collection kits for Clinical Trials, Commercial DNA Testing, Clinical Monitoring Programs and Post Marketing Surveillance, both inside and outside Eurofins. Eurofins Central Laboratory is a turnkey provider which deploys lean, globally standardized processes, enabling high quality GMP and FDA compliant specimen and transportation kits to be distributed worldwide.
Tim graduated as Clinical Chemistry Technician at the Radius College in Breda, the Netherlands and is travelling around the world as one of Eurofins Central Laboratory’s Travelling Laboratory Technicians. Tim is one of Eurofins’ Quiet Heroes, standing between you and the hazards of an ever-changing, highly complex world, making sure you can trust the medicines you depend on.
Eurofins Central Laboratory is a member of Eurofins BioPharma Services, a division of Eurofins Scientific, (hereinafter sometimes “Eurofins” or “the Group”). As a member of the Group, we are pleased to release to you our Q3 2019 earnings. Over the first nine months of 2019, total revenues grew 23.6% to EUR 3,335m vs. EUR 2,698m during the same period last year. Eurofins continues to express strong organic growth of 6.4% reported in Q3 2019. In Western Europe and North America, Eurofins BioPharma Services continued to perform exceptionally, with a double digit organic growth in Q3 2019 thanks to sustained, above market and overall growth as strategic outsourcing remains strong in the biopharmaceutical industry.
Prevention and Treatment of Cancer is the Most Significant Topic of the 21st Century
In 2018, there were 18 million reported cancer cases worldwide. This month, our Quiet Heroes behind the scenes at Eurofins Central Laboratory stand with the Leukemia & Lymphoma Society in recognizing September as Blood Cancer Awareness Month. Some of these cancers include:
The largest internal organ in the human body is the liver. The liver aids in digestion, energy storage, removal of toxins from the body, and supports many other functions. Because of the important job requirements set forth for this internal organ, evolution has assured us complete regeneration, so long as 25% of the tissue remaining is healthy.
Eurofins BioPharma Services will be attending the DIA Global Annual Meeting in San Diego, CA, June 23-27! Join us at Booth 1705 to discover how our dedicated BioPharma laboratories provide seamless, end-to-end solutions to help customers progress through the drug development cycle through a single, experienced provider!
For the 2019 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 60 contract research organizations were assessed on over 20 performance metrics in ISR's annual CRO Quality Benchmarking survey. Eurofins is recognized as a recipient of these awards, exceeding customer expectations in every category.
With Dr. Marks’ (Director, Center for Biologics Evaluation and Research), recent perspective on FDA’s Effort to Advance the Development of Gene Therapy, he thoughtfully highlights the recent successes of approved gene therapies, highlights the expert resourcing within FDA, CBER and NIH being applied towards this therapeutic specialization and details the innovative programs and committees (Novel and Exceptional Technology and Research Advisory Committee (NExTRAC), Regenerative Medicine Advanced Therapy (RMAT) designation and the INTERACT program) being instituted and enacted by the FDA. In addition, he highlights the critical issue facing success of this scientific endeavor, is quality manufacturing capacity but attentively details FDA action of awarding grants dedicated to industry stakeholders for the advancement of manufacturing technologies.
On January 27th, Eurofins Central Laboratory recognizes World Leprosy Day with the World Health Organization (WHO). Also known as Hansen’s disease, Leprosy is a chronic infectious disease caused by Mycobacterium Leprae. This disease affects the skin, peripheral nerves, mucus membranes of the upper respiratory tract, and eyes. Individuals affected will experience sensory loss in these affected areas as well as damaged thickened nerves.
In the realm of infectious disease, antibiotic resistance is a real and ever increasing concern across the entire healthcare industry. This is also true for ocular infections. With bacterial conjunctivitis being the second most common cause (versus viral conjunctivitis), diligent epidemiology and surveillance monitoring brings valued insight to us all. Eurofins Central Laboratory is proud to have provided analytical services (microbiological species confirmation and antibiotic resistance profile determination) to one of the only two nationwide multi-center surveillance studies (Antibiotic Resistance Monitoring in Ocular Microorganisms - ARMOR) ever undertaken in this indication. Article can be downloaded here.